From Financial Modeling Prep: 2025-02-18 11:45:00

Medtronic (NYSE:MDT) beat third-quarter earnings expectations but missed revenue forecasts, causing shares to drop over 7%. The company reaffirmed full-year guidance, citing strength in key segments. Adjusted EPS was $1.39, above the $1.36 estimate, while revenue was $8.29 billion, slightly below the $8.33 billion forecast.

Revenue grew 2.5% reported and 4.1% organically. Cardiovascular and Neuroscience segments saw 5% organic growth, with Diabetes segment up 10.4% organically. Strong demand for cardiac ablation and neuromodulation products drove growth.

Medtronic expects organic revenue growth of 4.75%-5% and adjusted EPS of $5.44-$5.50 for fiscal 2025, compared to current analyst consensus of $5.45 per share. The company remains optimistic about its performance in the coming years.



Read more at Financial Modeling Prep:: Medtronic Plunges 7% After Mixed Q3 Results